BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 23880152)

  • 1. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
    Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
    Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Zivanovic O; Eisenhauer EL; Zhou Q; Iasonos A; Sabbatini P; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):287-92. PubMed ID: 17996927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.
    Aletti GD; Podratz KC; Cliby WA; Gostout BS
    Gynecol Oncol; 2009 Jan; 112(1):22-7. PubMed ID: 18947860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
    Chi DS; Franklin CC; Levine DA; Akselrod F; Sabbatini P; Jarnagin WR; DeMatteo R; Poynor EA; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2004 Sep; 94(3):650-4. PubMed ID: 15350354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
    Eitan R; Levine DA; Abu-Rustum N; Sonoda Y; Huh JN; Franklin CC; Stevens TA; Barakat RR; Chi DS
    Cancer; 2005 Apr; 103(7):1397-401. PubMed ID: 15726548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
    Bristow RE; Montz FJ
    Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
    Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Shih KK; Chi DS; Barakat RR; Leitao MM
    Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.
    Todo Y; Sakuragi N; Oikawa M; Negishi H; Yamamoto R; Yoshiaki K; Tsumura N; Kawaguchi I; Fujimoto S
    Int J Clin Oncol; 2003 Apr; 8(2):90-6. PubMed ID: 12720101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
    Massari R; Barone M; Basilico R; Carella C; Colasante A; De Tursi M; Filippone A; Guetti L; Mani A
    Minerva Chir; 2014 Feb; 69(1):17-26. PubMed ID: 24675243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.